Immutep Ltd (IMM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immutep Ltd (IMM) has a cash flow conversion efficiency ratio of -0.233x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-33.50 Million ≈ $-23.71 Million USD) by net assets (AU$143.64 Million ≈ $101.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immutep Ltd (IMM) net asset quality to measure how much of total assets are equity-financed.
Immutep Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Immutep Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Immutep Ltd (IMM) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Immutep Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senheng New Retail Bhd
KLSE:5305
|
0.046x |
|
Klimasan Klima Sanayi ve Ticaret AS
IS:KLMSN
|
0.149x |
|
VOC Energy Trust
NYSE:VOC
|
1.128x |
|
PA Nova S.A.
WAR:NVA
|
-0.001x |
|
Leading Edge Materials Corp
V:LEM
|
-0.032x |
|
Wikana SA
WAR:WIK
|
0.073x |
|
Black Hawk Acquisition Corporation
NASDAQ:BKHA
|
-0.005x |
|
Accelerate Property Fund Ltd
JSE:APF
|
0.025x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Immutep Ltd (IMM) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$143.64 Million ≈ $101.63 Million |
AU$-62.05 Million ≈ $-43.90 Million |
-0.432x | -135.12% |
| 2024-06-30 | AU$189.52 Million ≈ $134.10 Million |
AU$-34.82 Million ≈ $-24.64 Million |
-0.184x | +30.12% |
| 2023-06-30 | AU$136.47 Million ≈ $96.56 Million |
AU$-35.88 Million ≈ $-25.39 Million |
-0.263x | +18.17% |
| 2022-06-30 | AU$94.08 Million ≈ $66.57 Million |
AU$-30.23 Million ≈ $-21.39 Million |
-0.321x | -33.47% |
| 2021-06-30 | AU$73.27 Million ≈ $51.84 Million |
AU$-17.64 Million ≈ $-12.48 Million |
-0.241x | +26.04% |
| 2020-06-30 | AU$33.30 Million ≈ $23.56 Million |
AU$-10.84 Million ≈ $-7.67 Million |
-0.326x | +48.07% |
| 2019-06-30 | AU$24.39 Million ≈ $17.26 Million |
AU$-15.29 Million ≈ $-10.82 Million |
-0.627x | -176573.57% |
| 2018-06-30 | AU$33.52 Million ≈ $23.72 Million |
AU$-11.89K ≈ $-8.42K |
0.000x | +99.89% |
| 2017-06-30 | AU$26.53 Million ≈ $18.77 Million |
AU$-8.51 Million ≈ $-6.02 Million |
-0.321x | -0.12% |
| 2016-06-30 | AU$35.32 Million ≈ $24.99 Million |
AU$-11.31 Million ≈ $-8.00 Million |
-0.320x | -1.53% |
| 2015-06-30 | AU$24.69 Million ≈ $17.47 Million |
AU$-7.79 Million ≈ $-5.51 Million |
-0.315x | +49.92% |
| 2014-06-30 | AU$22.59 Million ≈ $15.99 Million |
AU$-14.23 Million ≈ $-10.07 Million |
-0.630x | -14.85% |
| 2013-06-30 | AU$29.25 Million ≈ $20.70 Million |
AU$-16.04 Million ≈ $-11.35 Million |
-0.548x | -6.56% |
| 2012-06-30 | AU$37.16 Million ≈ $26.29 Million |
AU$-19.12 Million ≈ $-13.53 Million |
-0.515x | -190.62% |
| 2011-06-30 | AU$55.10 Million ≈ $38.99 Million |
AU$-9.76 Million ≈ $-6.90 Million |
-0.177x | +54.00% |
| 2010-06-30 | AU$16.79 Million ≈ $11.88 Million |
AU$-6.46 Million ≈ $-4.57 Million |
-0.385x | +62.96% |
| 2009-06-30 | AU$1.81 Million ≈ $1.28 Million |
AU$-1.88 Million ≈ $-1.33 Million |
-1.039x | -76.06% |
| 2008-06-30 | AU$2.63 Million ≈ $1.86 Million |
AU$-1.55 Million ≈ $-1.10 Million |
-0.590x | +27.67% |
| 2007-06-30 | AU$4.08 Million ≈ $2.89 Million |
AU$-3.33 Million ≈ $-2.36 Million |
-0.816x | -2.03% |
| 2006-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-5.05 Million ≈ $-3.57 Million |
-0.800x | -40.92% |
| 2005-06-30 | AU$8.34 Million ≈ $5.90 Million |
AU$-4.73 Million ≈ $-3.35 Million |
-0.568x | +48.43% |
| 2004-06-30 | AU$5.13 Million ≈ $3.63 Million |
AU$-5.64 Million ≈ $-3.99 Million |
-1.100x | -- |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more